These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29727562)

  • 21. Inhibition of RAF dimers: it takes two to tango.
    Cook FA; Cook SJ
    Biochem Soc Trans; 2021 Feb; 49(1):237-251. PubMed ID: 33367512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments.
    Zhang Q; Zhang X; You Q
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
    Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
    [No Abstract]   [Full Text] [Related]  

  • 25. Design, synthesis, and in vitro evaluation of N-(3-(3-alkyl-1H-pyrazol-5-yl) phenyl)-aryl amide for selective RAF inhibition.
    Jung H; Kim J; Im D; Moon H; Hah JM
    Bioorg Med Chem Lett; 2019 Feb; 29(4):534-538. PubMed ID: 30630714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation.
    Beneker CM; Rovoli M; Kontopidis G; Röring M; Galda S; Braun S; Brummer T; McInnes C
    J Med Chem; 2019 Apr; 62(8):3886-3897. PubMed ID: 30977659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies.
    Fu Y; Wang Y; Wan S; Li Z; Wang G; Zhang J; Wu X
    Molecules; 2017 Mar; 22(4):. PubMed ID: 28353640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group.
    Suijkerbuijk BM; Niculescu-Duvaz I; Gaulon C; Dijkstra HP; Niculescu-Duvaz D; Ménard D; Zambon A; Nourry A; Davies L; Manne HA; Friedlos F; Ogilvie LM; Hedley D; Lopes F; Preece NP; Moreno-Farre J; Raynaud FI; Kirk R; Whittaker S; Marais R; Springer CJ
    J Med Chem; 2010 Apr; 53(7):2741-56. PubMed ID: 20199087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stabilization of a closed kinase conformation induces RAF dimerization.
    Cancer Discov; 2013 Jul; 3(7):715. PubMed ID: 23847340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Discovery of Exarafenib (KIN-2787): Overcoming the Challenges of Pan-RAF Kinase Inhibition.
    Chen YK; Kanouni T; Arnold LD; Cox JM; Gardiner E; Grandinetti K; Jiang P; Kaldor SW; Lee C; Li C; Martin ES; Miller N; Murphy EA; Timple N; Tyhonas JS; Vassar A; Wang TS; Williams R; Yuan D; Kania RS
    J Med Chem; 2024 Feb; 67(3):1747-1757. PubMed ID: 38230963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
    Hong SP; Ahn SK
    Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
    Shao W; Mishina YM; Feng Y; Caponigro G; Cooke VG; Rivera S; Wang Y; Shen F; Korn JM; Mathews Griner LA; Nishiguchi G; Rico A; Tellew J; Haling JR; Aversa R; Polyakov V; Zang R; Hekmat-Nejad M; Amiri P; Singh M; Keen N; Dillon MP; Lees E; Ramurthy S; Sellers WR; Stuart DD
    Cancer Res; 2018 Mar; 78(6):1537-1548. PubMed ID: 29343524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemical Characterization of Full-Length Oncogenic BRAF
    Cope N; Novak B; Candelora C; Wong K; Cavallo M; Gunderwala A; Liu Z; Li Y; Wang Z
    Chembiochem; 2019 Nov; 20(22):2850-2861. PubMed ID: 31152574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling.
    Liu L; Lee MR; Kim JL; Whittington DA; Bregman H; Hua Z; Lewis RT; Martin MW; Nishimura N; Potashman M; Yang K; Yi S; Vaida KR; Epstein LF; Babij C; Fernando M; Carnahan J; Norman MH
    Bioorg Med Chem; 2016 May; 24(10):2215-34. PubMed ID: 27085672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance mechanism of the oncogenic β3-αC deletion mutation in BRAF kinase to dabrafenib and vemurafenib revealed by molecular dynamics simulations and binding free energy calculations.
    Niu Y; Zhang Y; Yao X
    Chem Biol Drug Des; 2019 Feb; 93(2):177-187. PubMed ID: 30225883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas.
    Sun Y; Alberta JA; Pilarz C; Calligaris D; Chadwick EJ; Ramkissoon SH; Ramkissoon LA; Garcia VM; Mazzola E; Goumnerova L; Kane M; Yao Z; Kieran MW; Ligon KL; Hahn WC; Garraway LA; Rosen N; Gray NS; Agar NY; Buhrlage SJ; Segal RA; Stiles CD
    Neuro Oncol; 2017 Jun; 19(6):774-785. PubMed ID: 28082416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.
    Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G
    Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapeutic drug selectivity between wild-type and mutant BRaf kinases in colon cancer.
    Zhang J; Ji T
    J Mol Model; 2017 Jan; 23(1):1. PubMed ID: 27921184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug Resistance Resulting from Kinase Dimerization Is Rationalized by Thermodynamic Factors Describing Allosteric Inhibitor Effects.
    Kholodenko BN
    Cell Rep; 2015 Sep; 12(11):1939-49. PubMed ID: 26344764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.